Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/9/2010

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the third quarter ended September 30, 2010.

Regarding the Company's ongoing review of strategic alternatives, Ronald Martell, chief executive officer of Poniard, said: "Poniard is actively focused on the execution of strategic alternatives aimed at optimizing the value of the Company and of our lead program, picoplatin.  This effort is our highest priority, and one for which the management team and its advisors are working diligently to achieve a successful outcome."

Third Quarter 2010 Unaudited Financial ResultsThe Company reported a net loss of $6.4 million ($0.13 diluted loss per share on a loss applicable to common shares of $6.5 million) for the quarter ended September 30, 2010, compared with a net loss of $9.9 million ($0.29 diluted loss per share on a loss applicable to common shares of $10.0 million) for the quarter ended September 30, 2009. For the first nine months of 2010, the net loss was $24.9 million ($0.55 diluted loss per share on a loss applicable to common shares of $25.6 million), compared to a net loss of $32.5 million ($0.95 diluted loss per share on a loss applicable to common shares of $32.9 million) for the same period in 2009.

Total operating expenses for the quarter ended September 30, 2010 were $6.0 million compared with $9.2 million for the quarter ended September 30, 2009. Year to date, total operating expenses were $23.2 million compared to $30.5 million for the first nine months of 2009.

Research and development expenses were $0.9 million for the quarter ended September 30, 2010, compared with $5.1 million for the quarter ended September 30, 2009. Year to date, research and development expenses were
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) ... Testing Market - Global Industry Analysis, Size, Share, ... report to their offering. ... one of the fastest growing markets globally. This ... health care awareness, preference of the people for ...
(Date:7/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ... "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, ... report to their offering. ... on of assay type, therapeutic area, and geography. ... been categorized into six major segments: cAMP assays, ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Transplant Patients Represents First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell ... Over a Decade ... ... 29 ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase ...
... be Presented at ASCO Shows Survival Benefit in Complete ... Partial Responders Compared with Chemotherapy Alone, BERKELEY ... GNTA) announced the results of long-term,followup from a Phase ... sodium) Injection, in patients with chronic,lymphocytic leukemia (CLL). With ...
Cached Medicine Technology:ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
(Date:7/27/2015)... ... 2015 , ... The FSH Society , the Massachusetts-based ... muscular dystrophy (FSHD), today announced the introduction of the first-ever care guideline for ... published today. , This new guideline condenses the results of nearly 60 ...
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... Looking ... healthy smile? Horizon Blue Cross Blue Shield of New Jersey has enhanced its Dental ... to take care of their teeth. , “Horizon is committed to offering our ...
(Date:7/27/2015)... AZ (PRWEB) , ... July 27, 2015 , ... The ... who are aging out of the foster care system to get into and complete ... Charitable Trust, was introduced at an event today with partners from across the ...
(Date:7/27/2015)... ... July 27, 2015 , ... A Harris County jury awarded a group ... Canadian stock promoter Robert Kubbernus based on findings of fraud and violations of the ... by the court in Cause No. 2010-09675; Jo Ann Schermerhorn, et al v. CenturyLink, ...
(Date:7/27/2015)... ... July 27, 2015 , ... With a new charity program ... to support its mission of reducing the number of deaths and injuries occurring from ... and their families. PursuitSAFETY works with the police to find better and safer ...
Breaking Medicine News(10 mins):Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 4Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 5Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 6Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3
... model that looks at different strategies for curbing ... isolation may be effective approaches when patients are ... superbugs, such as methicillin-resistant Staphylococcus aureas (MRSA), and ... infections, this type of modeling, if used to ...
... problem that needs to be addressed next is the epidemic ... together to discuss the latest in pain research and treatment ... Pain Medicine (AAPM), February 12-16 at the Gaylord Palms in ... help of their physicians, have been asked to stop smoking ...
... otherwise healthy people have similar survival rates to younger ... older patients can undergo lung transplantation and have good ... patients from having the procedure, a new study says. ... Medical Center reviewed the records of 48 UCLA patients ...
... Proposed Changes in ... Lifesaving Effort, WASHINGTON, Feb. 16 As President Bush ... funded by the,President,s Emergency Plan for AIDS Relief (PEPFAR), the ... request, AIDS Healthcare,Foundation (AHF) ( http://www.aidshealth.org ) today cautioned the ...
... release is also available in French . ... flushing toxic chemicals into the ecosystem through municipal sewer ... comes from an unlikely source: estrogen. , After an ... amounts of estrogen present in municipal wastewater discharges can ...
... Crowder &,DeGaris, P.C. (http://www.cwcd.com ), has filed ... the United States, who allegedly suffered,permanent kidney damage ... to prevent excessive bleeding during coronary,artery bypass graft ... to CBS News, 60 Minutes will report Sunday ...
Cached Medicine News:Health News:Mathematical modeling offers new approaches to fight dual-resistant hospital infections 2Health News:Physicians focus on stopping pain epidemic 2Health News:Physicians focus on stopping pain epidemic 3Health News:Physicians focus on stopping pain epidemic 4Health News:Physicians focus on stopping pain epidemic 5Health News:Physicians focus on stopping pain epidemic 6Health News:Good Outcomes Possible for Older Lung Transplant Patients 2Health News:Bush AIDS Legacy at Risk, Says AHF 2Health News:Fish devastated by sex-changing chemicals in municipal wastewater 2Health News:Fish devastated by sex-changing chemicals in municipal wastewater 3Health News:60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG 2
Bone Curette, 160 mm...
Bone Currettes...
London Endocervical Curette is a stainless-steel curette for obtaining endocervical samples with minimal effort....
...
Medicine Products: